Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3910 |
Name | lung adenocarcinoma |
Definition | A lung non-small cell carcinoma that derives_from epithelial cells of glandular origin. |
Source | DiseaseOntology.org |
Alt Ids | DOID:4826 DOID:3909 |
Path | disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer lung carcinoma lung non-small cell carcinoma lung adenocarcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
MAP2K1 K57N | Selumetinib | lung adenocarcinoma | sensitive | detail... |
PIK3CA H1047R | Dactolisib | lung adenocarcinoma | sensitive | detail... |
PIK3CA H1047R | Sirolimus | lung adenocarcinoma | no benefit | detail... |
FBXW7 R465H | Temsirolimus | lung adenocarcinoma | sensitive | detail... |
ROS1 rearrange | Crizotinib | lung adenocarcinoma | sensitive | detail... |
ALK rearrange ALK I1171T | Alectinib | lung adenocarcinoma | resistant | detail... |
ALK rearrange ALK I1171T | Crizotinib | lung adenocarcinoma | resistant | detail... |
MAP2K1 Q56P | Trametinib | lung adenocarcinoma | sensitive | detail... |
MAP2K1 Q56P | Selumetinib | lung adenocarcinoma | sensitive | detail... |
MAP2K1 Q56P | Refametinib | lung adenocarcinoma | sensitive | detail... |
MAP2K1 Q56P | PD-0325901 | lung adenocarcinoma | sensitive | detail... |
BRAF mutant | Trametinib | lung adenocarcinoma | sensitive | detail... |
NRAS mutant | Trametinib | lung adenocarcinoma | resistant | detail... |
ABL1 R332W | Imatinib | lung adenocarcinoma | sensitive | detail... |
ABL1 G321L | Imatinib | lung adenocarcinoma | sensitive | detail... |
ABL1 T315I ABL1 R332W | Imatinib | lung adenocarcinoma | resistant | detail... |
ABL1 R332W | Dasatinib | lung adenocarcinoma | sensitive | detail... |
ABL1 G321L | Dasatinib | lung adenocarcinoma | sensitive | detail... |
ABL1 T315I ABL1 R332W | Dasatinib | lung adenocarcinoma | resistant | detail... |
IDH1 mutant | Dasatinib | lung adenocarcinoma | resistant | detail... |
FGFR1 positive | AZD8055 + Fexagratinib | lung adenocarcinoma | sensitive | detail... |
FGFR1 positive | Fexagratinib + Vistusertib | lung adenocarcinoma | sensitive | detail... |
FGFR1 positive | Fexagratinib + Sirolimus | lung adenocarcinoma | sensitive | detail... |
BRAF G469L | Vemurafenib | lung adenocarcinoma | no benefit | detail... |
BRAF N581S | PF-00477736 + PF3644022 | lung adenocarcinoma | predicted - sensitive | detail... |
FGFR3 positive | Rogaratinib | lung adenocarcinoma | predicted - sensitive | detail... |
BRAF G469A | PLX8394 | lung adenocarcinoma | sensitive | detail... |
BRAF G466V | PLX8394 | lung adenocarcinoma | sensitive | detail... |
BRAF V600E BRAF amp | SCH772984 | lung adenocarcinoma | decreased response | detail... |
BRAF V600E BRAF amp | Dabrafenib + SCH772984 + Trametinib | lung adenocarcinoma | sensitive | detail... |
ALK rearrange ALK G1123S | Ceritinib | lung adenocarcinoma | predicted - resistant | detail... |
ALK rearrange ALK G1123S | Alectinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK C1156Y ALK L1196M | Crizotinib | lung adenocarcinoma | predicted - resistant | detail... |
FGFR1 amp | PRN1371 | lung adenocarcinoma | sensitive | detail... |
BRAF V600E NRAS Q61K | Dabrafenib + Trametinib | lung adenocarcinoma | predicted - resistant | detail... |
ALK rearrange ALK L1152R | Alectinib | lung adenocarcinoma | predicted - sensitive | detail... |
ALK rearrange ALK L1152R | Ceritinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK L1196M | Crizotinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK F1174L ALK G1269A | Belizatinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK F1174L ALK D1203N ALK G1269A | Ceritinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK L1256F | Lorlatinib | lung adenocarcinoma | resistant | detail... |
EML4 - ALK ALK L1256F | Alectinib | lung adenocarcinoma | sensitive | detail... |
EML4 - ALK ALK T1151K | Crizotinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK T1151K | Ceritinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK | Crizotinib | lung adenocarcinoma | predicted - sensitive | detail... |
ALK rearrange ALK L1196M | Crizotinib | lung adenocarcinoma | predicted - resistant | detail... |
ALK rearrange ALK L1196M ALK D1203N | Ceritinib | lung adenocarcinoma | predicted - resistant | detail... |
ALK rearrange ALK L1196M ALK D1203N | Lorlatinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK C1156Y ALK G1269A | Lorlatinib | lung adenocarcinoma | unknown | detail... |
ALK rearrange ALK C1156Y | Lorlatinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK C1156Y ALK G1269A | Lorlatinib + Saracatinib | lung adenocarcinoma | sensitive | detail... |
ALK rearrange ALK C1156Y | Lorlatinib + Saracatinib | lung adenocarcinoma | sensitive | detail... |
EML4 - ALK ALK E1154K ALK G1202R ALK I1268V | Crizotinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK E1154K ALK G1202R ALK I1268V | Ceritinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK G1202R | Brigatinib | lung adenocarcinoma | conflicting | detail... |
EML4 - ALK ALK T1151M ALK C1156Y ALK F1174L ALK G1202R ALK S1206F ALK G1269A | Lorlatinib | lung adenocarcinoma | predicted - resistant | detail... |
ALK rearrange ALK G1269A | Crizotinib | lung adenocarcinoma | predicted - resistant | detail... |
ALK rearrange ALK F1174L | Ceritinib | lung adenocarcinoma | predicted - resistant | detail... |
TP53 R181L | Doxorubicin + Nutlin-3a | lung adenocarcinoma | sensitive | detail... |
TP53 R175P | Doxorubicin + Nutlin-3a | lung adenocarcinoma | no benefit | detail... |
TP53 R181E | Doxorubicin + Nutlin-3a | lung adenocarcinoma | sensitive | detail... |
RET rearrange | Cabozantinib | lung adenocarcinoma | predicted - sensitive | detail... |
BRAF G464V | Trametinib | lung adenocarcinoma | no benefit | detail... |
BRAF G466A | Trametinib | lung adenocarcinoma | no benefit | detail... |
BRAF D594G | Trametinib | lung adenocarcinoma | no benefit | detail... |
BRAF N581S | Trametinib | lung adenocarcinoma | no benefit | detail... |
BRAF G466V | Trametinib | lung adenocarcinoma | no benefit | detail... |
BRAF G469A | Trametinib | lung adenocarcinoma | conflicting | detail... |
CDKN2A loss | Palbociclib | lung adenocarcinoma | predicted - sensitive | detail... |
PIK3CA mutant | Capivasertib | lung adenocarcinoma | no benefit | detail... |
PTEN mutant | Capivasertib | lung adenocarcinoma | no benefit | detail... |
EML4 - ALK | Alvocidib | lung adenocarcinoma | sensitive | detail... |
EML4 - ALK | Dinaciclib | lung adenocarcinoma | sensitive | detail... |
EML4 - ALK | Alvocidib + Crizotinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK | THZ1 | lung adenocarcinoma | sensitive | detail... |
ALK rearrange | Conteltinib | lung adenocarcinoma | predicted - sensitive | detail... |
BRAF V600E | Trametinib | lung adenocarcinoma | predicted - sensitive | detail... |
ALK rearrange | Bevacizumab + Lorlatinib | lung adenocarcinoma | predicted - sensitive | detail... |
BRAF L597R | Dabrafenib + Trametinib | lung adenocarcinoma | predicted - sensitive | detail... |
BRAF G469V | Dabrafenib + Trametinib | lung adenocarcinoma | no benefit | detail... |
BRAF L597V | Dabrafenib + Trametinib | lung adenocarcinoma | sensitive | detail... |
BRAF L597V | Trametinib | lung adenocarcinoma | sensitive | detail... |
BRAF L597V | Lifirafenib | lung adenocarcinoma | sensitive | detail... |
BRAF L597V | LXH 254 | lung adenocarcinoma | sensitive | detail... |
BRAF G469A | Dabrafenib + Trametinib | lung adenocarcinoma | sensitive | detail... |
BRAF G469A | Lifirafenib | lung adenocarcinoma | sensitive | detail... |
BRAF G469A | LXH 254 | lung adenocarcinoma | sensitive | detail... |
BRAF L597V | Dabrafenib | lung adenocarcinoma | resistant | detail... |
BRAF L597V | Encorafenib | lung adenocarcinoma | resistant | detail... |
BRAF L597V | Vemurafenib | lung adenocarcinoma | resistant | detail... |
BRAF L597V | Tovorafenib | lung adenocarcinoma | resistant | detail... |
BRAF G469A | Dabrafenib | lung adenocarcinoma | resistant | detail... |
BRAF G469A | Vemurafenib | lung adenocarcinoma | resistant | detail... |
BRAF G469A | Tovorafenib | lung adenocarcinoma | resistant | detail... |
BRAF L597V | LY3214996 | lung adenocarcinoma | resistant | detail... |
BRAF L597V | MK-8353 | lung adenocarcinoma | resistant | detail... |
BRAF L597V | Ravoxertinib | lung adenocarcinoma | resistant | detail... |
BRAF L597V | Ulixertinib | lung adenocarcinoma | resistant | detail... |
BRAF G469A | Ulixertinib | lung adenocarcinoma | resistant | detail... |
BRAF G469A | Ravoxertinib | lung adenocarcinoma | resistant | detail... |
BRAF G469A | MK-8353 | lung adenocarcinoma | resistant | detail... |
BRAF G469A | LY3214996 | lung adenocarcinoma | resistant | detail... |
EML4 - RET | RXDX-105 | lung adenocarcinoma | sensitive | detail... |
EML4 - RET | Pralsetinib | lung adenocarcinoma | sensitive | detail... |
EML4 - RET | Ponatinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - RET | Trametinib | lung adenocarcinoma | conflicting | detail... |
EML4 - RET | RXDX-105 + Trametinib | lung adenocarcinoma | no benefit | detail... |
EML4 - RET | GSK2126458 + RXDX-105 | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - RET | Volasertib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK S1206F | Crizotinib | lung adenocarcinoma | predicted - sensitive | detail... |
RET rearrange | Sunitinib | lung adenocarcinoma | no benefit | detail... |
EML4 - ALK ALK Q1188_L1190del | Lorlatinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK G1202K | Lorlatinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK A1200_G1201delinsW | Alectinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK A1200_G1201delinsW | Brigatinib | lung adenocarcinoma | predicted - sensitive | detail... |
ALK rearrange ROS1 rearrange | Crizotinib | lung adenocarcinoma | predicted - sensitive | detail... |
ARID2 - ALK EML4 - ALK | Crizotinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK | Alectinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK | Ceritinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK | Lorlatinib | lung adenocarcinoma | sensitive | detail... |
EML4 - ALK | Brigatinib | lung adenocarcinoma | sensitive | detail... |
EML4 - ALK ALK I1171N ALK V1180L | Alectinib | lung adenocarcinoma | predicted - resistant | detail... |
ALK fusion | Lorlatinib | lung adenocarcinoma | predicted - sensitive | detail... |
ALK fusion | Crizotinib | lung adenocarcinoma | predicted - sensitive | detail... |
ALK fusion | Alectinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK F1174C ALK E1210K | Lorlatinib | lung adenocarcinoma | predicted - sensitive | detail... |
BRAF G469A BRAF W604C | Dabrafenib + Trametinib | lung adenocarcinoma | predicted - sensitive | detail... |
BRAF K601E | Dabrafenib + Trametinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK G1202R | Alectinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK G1202R | Lorlatinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK T1151K ALK G1202R ALK S1206F | Lorlatinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK G1202L | Lorlatinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK E1129V ALK I1171T ALK F1174C ALK F1174L ALK F1174V ALK G1269A | Crizotinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK E1129V ALK I1171T ALK F1174C ALK F1174L ALK F1174V ALK G1269A | Brigatinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK F1174C | Lorlatinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK F1174C ALK L1196M | Lorlatinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK BRAF V600E | Dabrafenib + Trametinib | lung adenocarcinoma | no benefit | detail... |
EML4 - ALK BRAF V600E | Alectinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK I1171S | Crizotinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK I1171S | Ceritinib | lung adenocarcinoma | predicted - sensitive | detail... |
ALK rearrange ALK T1151R | Ceritinib | lung adenocarcinoma | predicted - resistant | detail... |
ALK rearrange ALK T1151R | Brigatinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK I1171S | Alectinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK I1171S | Brigatinib | lung adenocarcinoma | predicted - sensitive | detail... |
BRAF T599dup | Dabrafenib + Trametinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK BRAF A598_T599insV | Alectinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK F1174L ALK S1189C | Crizotinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK F1174L ALK S1189C | Ceritinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK | Ensartinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK I1171N | Alectinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK I1171N | Ensartinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK I1171N ALK G1202R | Lorlatinib | lung adenocarcinoma | predicted - sensitive | detail... |
BRAF V600E MAP2K1 K57N | Dabrafenib + Trametinib | lung adenocarcinoma | predicted - resistant | detail... |
BRAF V600E PTEN N329fs | Dabrafenib | lung adenocarcinoma | predicted - resistant | detail... |
ALK positive | Alectinib | lung adenocarcinoma | predicted - sensitive | detail... |
ALK rearrange | Alectinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK F1174L ALK E1210K | Brigatinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK F1174L ALK E1210K ALK G1269A | Lorlatinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK I1171T ALK F1174L ALK L1196M ALK D1203N ALK E1210K ALK G1269A | Lorlatinib | lung adenocarcinoma | predicted - resistant | detail... |
ALK D1225N | Crizotinib | lung adenocarcinoma | predicted - sensitive | detail... |
ALK D1225N | Ensartinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK A1200V | Crizotinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK V1180L | Alectinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK G1269A | Crizotinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK IDH2 R140Q | Alectinib | lung adenocarcinoma | predicted - resistant | detail... |
ALK del exon2-19 | Alectinib | lung adenocarcinoma | predicted - sensitive | detail... |
BRAF G469V | Gefitinib | lung adenocarcinoma | sensitive | detail... |
BRAF G469V | Afatinib | lung adenocarcinoma | sensitive | detail... |
BRAF G469V | Osimertinib | lung adenocarcinoma | sensitive | detail... |
EML4 - ALK ALK D1203N | Crizotinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK D1203N | Lorlatinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK L1196M ALK D1203N | Lorlatinib | lung adenocarcinoma | predicted - resistant | detail... |
ALK fusion | Brigatinib | lung adenocarcinoma | predicted - sensitive | detail... |
BRAF G466V | Dabrafenib + Trametinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK G1269A | Brigatinib | lung adenocarcinoma | sensitive | detail... |
EML4 - ALK ALK G1269A | Ceritinib | lung adenocarcinoma | sensitive | detail... |
BRAF N486_P490del | Dabrafenib + Trametinib | lung adenocarcinoma | predicted - sensitive | detail... |
ATM E473* ATM loss | ART0380 | lung adenocarcinoma | sensitive | detail... |
CDKN2A A17fs | Palbociclib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK I1171N | Brigatinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK I1171N | Lorlatinib | lung adenocarcinoma | predicted - sensitive | detail... |
BRAF V600_W604delinsR | Dabrafenib + Trametinib | lung adenocarcinoma | predicted - sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | lung adenocarcinoma | predicted - sensitive | detail... |
BRAF D594N | NST-628 | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK R1181H | Crizotinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK R1181H | Brigatinib | lung adenocarcinoma | sensitive | detail... |
EML4 - ALK ALK G1128A ALK R1192P | Crizotinib | lung adenocarcinoma | predicted - resistant | detail... |
ROS1 rearrange ROS1 L2086F | Cabozantinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK F1174C | Crizotinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK F1174C | Alectinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK F1174C ALK V1180L | Alectinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK F1174C ALK V1180L | Bevacizumab + Lorlatinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK L1196M ALK G1269A | Alectinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK L1196M ALK G1269A | Ceritinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK L1122V ALK L1196M ALK D1203N ALK G1269A | Ceritinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK E803Q ALK V1180L | Alectinib | lung adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK ALK F1174C ALK G1202R | NVL-655 | lung adenocarcinoma | sensitive | detail... |
EML4 - ALK ALK G1202R ALK G1269A | NVL-655 | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK | NVL-655 | lung adenocarcinoma | sensitive | detail... |
ALK fusion ALK G1202R | Lorlatinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK F1174V | Lorlatinib | lung adenocarcinoma | predicted - sensitive | detail... |
EML4 - ALK ALK V1180L | Ceritinib | lung adenocarcinoma | predicted - sensitive | detail... |
ALK fusion ALK C1156Y | Alectinib | lung adenocarcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01579994 | Phase I | Crizotinib + Ganetespib | Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers | Completed | USA | 0 |
NCT01737502 | Phase Ib/II | Auranofin + Sirolimus | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer | Completed | USA | 0 |
NCT01814553 | Phase III | Afatinib + Loperamide | ADAM-Afatinib Diarrhea Assessment and Management | Completed | USA | 0 |
NCT01877083 | Phase II | Lenvatinib | Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung | Completed | USA | 4 |
NCT01877811 | Phase Ib/II | RXDX-105 | CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2 | Completed | USA | 0 |
NCT01976741 | Phase I | Rogaratinib | Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor | Completed | USA | FRA | ESP | DEU | CHE | 2 |
NCT02185690 | Phase I | Binimetinib + Carboplatin + Pemetrexed Disodium | A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung | Completed | CAN | 0 |
NCT02231164 | Phase III | Docetaxel Nintedanib | LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research | Terminated | USA | 2 |
NCT02264678 | Phase Ib/II | Ceralasertib Carboplatin + Ceralasertib Ceralasertib + Durvalumab Ceralasertib + Olaparib | Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents | Recruiting | USA | HUN | GBR | FRA | ESP | CAN | BEL | AUS | 1 |
NCT02285855 | Phase II | Metformin | Metformin in Non Small Cell Lung Cancer (NSCLC) | Terminated | USA | 0 |
NCT02450175 | Phase I | Letrozole Everolimus | Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls | Unknown status | USA | 0 |
NCT02450591 | Phase I | Erlotinib | Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations | Completed | USA | 0 |
NCT02466568 | Phase Ib/II | Nivolumab | Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung | Withdrawn | 0 | |
NCT02503358 | Phase I | Paclitaxel + Selumetinib | Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT02513667 | Phase II | Ceritinib | Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma | Terminated | USA | 0 |
NCT02705339 | Phase II | Rociletinib | Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC) | Withdrawn | 0 | |
NCT02759835 | Phase II | Osimertinib | Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib | Completed | USA | 0 |
NCT02839681 | Phase II | Anetumab ravtansine | Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma | Terminated | USA | 0 |
NCT02856425 | Phase I | Nintedanib + Pembrolizumab | Trial Of Pembrolizumab And Nintedanib (PEMBIB) | Recruiting | FRA | 0 |
NCT02864992 | Phase II | Tepotinib | Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) | Active, not recruiting | USA | POL | NLD | ITA | ISR | FRA | ESP | DEU | CHE | BEL | AUT | 4 |
NCT03076164 | Phase Ib/II | Erlotinib + Trametinib | A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib | Completed | USA | 0 |
NCT03102320 | Phase I | Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin | Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) | Completed | USA | NLD | ITA | GBR | FRA | ESP | CHE | CAN | BEL | AUS | 2 |
NCT03255083 | Phase I | DS-1205c + Osimertinib | DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | Terminated | 1 | |
NCT03371381 | Phase Ib/II | JNJ-64041757 + Nivolumab Nivolumab | An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung | Terminated | USA | ESP | BEL | 0 |
NCT03476681 | Phase I | NEO-201 | QUILT-3.017: Study of NEO-201 in Solid Tumors | Recruiting | USA | 0 |
NCT03696212 | Phase Ib/II | Grapiprant + Pembrolizumab | Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma | Terminated | USA | 0 |
NCT03704688 | Phase Ib/II | Ponatinib + Trametinib | Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT03709147 | Phase II | Carboplatin + Metformin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Metformin + Pembrolizumab + Pemetrexed Disodium | Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma (FAME) | Unknown status | ITA | 0 |
NCT03865511 | Phase II | Osimertinib | MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib (MELROSE) | Active, not recruiting | FRA | 0 |
NCT03894618 | Phase I | SL-279252 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | Completed | USA | ESP | CAN | BEL | 0 |
NCT03944772 | Phase II | Necitumumab + Osimertinib Osimertinib + Selpercatinib Alectinib + Osimertinib Carboplatin + Durvalumab + Pemetrexed Disodium Osimertinib + Savolitinib Gefitinib + Osimertinib | Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (ORCHARD) | Active, not recruiting | USA | SWE | NOR | NLD | ITA | ESP | DNK | 2 |
NCT03970746 | Phase Ib/II | PDC*lung01 + Pembrolizumab PDC*lung01 + Pemetrexed Disodium PDC*lung01 | Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC | Active, not recruiting | POL | NLD | FRA | DEU | BEL | 0 |
NCT04022876 | Phase I | ALRN-6924 + Carboplatin + Pemetrexed Disodium ALRN-6924 + Topotecan Carboplatin + Pemetrexed Disodium | A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) | Terminated | USA | POL | ITA | ESP | DEU | 2 |
NCT04105270 | Phase II | Carboplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium | RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial | Recruiting | USA | 0 |
NCT04145622 | Phase Ib/II | Ifinatamab deruxtecan | Study of DS-7300a in Participants With Advanced Solid Malignant Tumors | Recruiting | USA | 1 |
NCT04180371 | Phase Ib/II | BT5528 + Nivolumab BT5528 | Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | Recruiting | USA | GBR | ESP | BEL | 1 |
NCT04245514 | Phase II | Durvalumab | Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC) | Recruiting | DEU | CHE | 0 |
NCT04263090 | Phase Ib/II | Nivolumab + Rigosertib | Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment | Completed | USA | 0 |
NCT04300556 | Phase Ib/II | MORAb-202 | A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRa)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | Recruiting | USA | GBR | FRA | ESP | 0 |
NCT04339218 | Phase III | Carboplatin + Pembrolizumab + Pemetrexed Disodium | Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma (CRYOMUNE) | Recruiting | FRA | 0 |
NCT04393298 | Phase Ib/II | UCB6114 Trifluridine-tipiracil hydrochloride + UCB6114 Fluorouracil + Leucovorin + Oxaliplatin + UCB6114 | A Study to Assess the Safety, Pharmacokinetics and Antitumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors | Completed | USA | GBR | 0 |
NCT04424641 | Phase Ib/II | GEN1044 | A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors | Terminated | USA | ISR | ESP | DNK | 0 |
NCT04545710 | Phase II | Abemaciclib + Osimertinib | Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance | Active, not recruiting | USA | 0 |
NCT04557449 | Phase I | Letrozole + PF-07220060 Fulvestrant + PF-07220060 PF-07220060 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i) | Recruiting | USA | SVK | GBR | CZE | ARG | 3 |
NCT04672434 | Phase I | Sym021 + Sym024 Sym024 | Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies | Active, not recruiting | USA | CAN | 0 |
NCT04682431 | Phase I | Pembrolizumab + PY159 PY159 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04691375 | Phase I | Pembrolizumab + PY314 PY314 | A Study of PY314 in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04748419 | Phase Ib/II | Durvalumab | Safety and Efficacy of Consolidative Hypofractionated Radiation Therapy (hfRT) for Boosting the Residual Primary Lung Cancer With Durvalumab | Recruiting | USA | 0 |
NCT04870034 | Phase I | Binimetinib + Palbociclib | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer | Withdrawn | USA | 0 |
NCT04939701 | Phase Ib/II | ASP0739 + Pembrolizumab ASP0739 | Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants | Terminated | USA | 0 |
NCT04973163 | Phase I | BI 1823911 + Midazolam BI 1701963 + BI 1823911 | A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation | Active, not recruiting | USA | GBR | ESP | BEL | 0 |
NCT04991025 | Phase II | Certolizumab pegol + Cisplatin + Gemcitabine + Nivolumab Certolizumab pegol + Cisplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Certolizumab pegol + Gemcitabine + Nivolumab Carboplatin + Certolizumab pegol + Nivolumab + Pemetrexed Disodium | Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery | Recruiting | USA | 0 |
NCT04991740 | Phase I | JNJ-78306358 | A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors | Completed | ISR | ESP | 0 |
NCT05015010 | Phase II | Alectinib | Alectinib in Neo-adjuvant Treatment of Stage III NSCLC (ALNEO) | Active, not recruiting | ITA | 0 |
NCT05038150 | Phase I | SGN1 | Study of SGN1 in Patients With Advanced Solid Tumor | Recruiting | USA | 1 |
NCT05101356 | Phase Ib/II | LabVax 3(22)-23 + Sargramostim LabVax 3(22)-23 + Pembrolizumab + Sargramostim | A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma | Recruiting | USA | 0 |
NCT05103345 | Phase I | SGN1 | Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor | Recruiting | 2 | |
NCT05198830 | Phase II | Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium + TRC102 | Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05240131 | Phase Ib/II | Atezolizumab + GB1211 | A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). | Active, not recruiting | POL | FRA | ESP | 0 |
NCT05254184 | Phase I | Ipilimumab + Nivolumab + Poly ICLC + Pooled Mutant KRAS-Targeted Long Peptide Vaccine | KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC | Recruiting | USA | 0 |
NCT05397093 | Phase I | ITIL-306 | ITIL-306 in Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT05498597 | Phase I | AMT-151 | AMT-151 in Patients With Selected Advanced Solid Tumours | Recruiting | AUS | 1 |
NCT05512377 | Phase II | BI 907828 | Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder | Active, not recruiting | USA | GBR | FRA | ESP | DEU | CHE | BEL | AUS | 5 |
NCT05577715 | Phase II | MORAb-202 | A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) | Terminated | USA | FRA | ESP | BEL | AUS | 1 |
NCT05607498 | Phase I | EMB-07 | First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors | Recruiting | AUS | 1 |
NCT05676749 | Phase I | Aldesleukin + C-TIL051 + Pembrolizumab | C-TIL051 in Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05693090 | Phase I | Osimertinib + Tipifarnib | Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer | Withdrawn | USA | 0 |
NCT05709821 | Phase Ib/II | Pembrolizumab IMM60 IMM60 + Pembrolizumab | IMM60 and Pembrolizumab in Melanoma and NSCLC | Terminated | USA | GBR | ESP | 0 |
NCT05733000 | Phase II | CPI-613 + Gemcitabine + Hydroxychloroquine CPI-613 + Hydroxychloroquine CPI-613 + Gemcitabine CPI-613 + Fluorouracil + Hydroxychloroquine | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | Recruiting | USA | 0 |
NCT05860296 | Phase Ib/II | Pembrolizumab + SLC-391 | Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers | Recruiting | USA | CAN | 0 |
NCT05948865 | Phase I | CPO301 | A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors | Recruiting | USA | CAN | 0 |
NCT05954871 | Phase I | Cetuximab + GDC-1971 GDC-1971 + Osimertinib | Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer | Active, not recruiting | USA | CAN | AUS | 1 |
NCT06014658 | Phase I | MBRC-101 | Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors | Recruiting | USA | 0 |
NCT06178614 | Phase I | JNJ-87890387 | A Study of JNJ-87890387 for Advanced Solid Tumors | Recruiting | USA | FRA | ESP | 0 |
NCT06225427 | Phase I | Gilteritinib | Gilteritinib for the Treatment of ALK NSCLC | Recruiting | USA | 0 |
NCT06240728 | Phase I | NPX887 | A Study of NPX887 for Participants With Solid Tumors Known to Express HHLA2/B7-H7 | Recruiting | USA | 0 |
NCT06495125 | Phase II | Defactinib + Nivolumab + RO5126766 | Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT06516887 | Phase Ib/II | Bemcentinib + Pacritinib | Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma | Not yet recruiting | USA | 0 |
NCT06526819 | Phase Ib/II | SMP-3124 | A Phase 1/2 Study of SMP-3124LP in Adults With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT06555263 | Phase II | Luveltamab Tazevibulin | Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT06564844 | Phase III | Tegafur-gimeracil-oteracil Potassium Etoposide AZD2936 + Datopotamab deruxtecan Carboplatin AZD2936 Vinorelbine Pemetrexed Disodium Cisplatin | A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) | Recruiting | USA | TUR | SWE | POL | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BEL | 7 |